Frederic Revah | Chief Executive Officer

Frederic Revah, Chief Executive Officer, Genethon

As the Chief Executive Officer of Genethon, Frédéric Revah has more than twenty years’ experience in the pharmaceutical and biotech industries as well as in academic research. Immediately prior to joining Genethon in January 2010, he had been Chief Executive Officer at Sepal Pharma (oncology), before which he was CEREP’s Vice-President of Drug Discovery and Scientific Director from 1999-2007, as well as being Chief Executive Officer of its oncology arm. He was also head of the CNS Gene Therapy Department and the Neurochemistry Department at Rhône-Poulenc Rorer (now Sanofi-Aventis) from 1992 to 1998.
Frédéric Revah started his career as an associate staff researcher at the Institut Pasteur (from 1990 to 1992). He obtained his doctorate at the Institut Pasteur / Université de Paris V in 1991, and graduated from the Ecole Polytechnique engineering school in 1985.


World Orphan Drug Congress USA 2018 - Conference Day One @ 09:45

Keynote CEO Panel: Gene therapy - a new paradigm for patients, new challenges for industry

  • Looking back at the commercial performance of the first generation of gene therapies- from proof of concept to the road to approval 
  • How will gene therapy innovation look in the next 10 years?
  • Considering potential new value propositions for patients, payers and the health care system
  • Strengthening clinical development, exploring novel technologies while maintaining safety- what needs to be improved? 

back to speakers